ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2632

The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory

Joshua Liu1, Kathleen Teves2, Van La2, Arlene Bravo3, Sheila Lezcano4, Talha Khawar4, Ebrahim Sadeghi4, Cong-Bin Wang5, Karina Torralba6, Howard Yang5 and Vaneet K. Sandhu7, 1Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, 2Internal Medicine, University of California, Riverside, Riverside, CA, 3Internal Medicine, Loma Linda University, Loma Linda, CA, 4Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, 5Loma Linda University Medical Center, Loma Linda, CA, 6Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA, 7Division of Rheumatology, Loma Linda University, Loma Linda, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: laboratory tests and registries, Lupus, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The Southern California Lupus Registry (SCOLR) is a population-based, longitudinal, multi-ethnic cohort of subjects with SLE directed toward studying health and healthcare disparities in the Inland Empire, an under-recognized region of southern California inhabiting more than 3 million individuals where the percentage population living below the federal poverty line exceeds the general population in California. We report herein a preliminary analysis of baseline characteristics and clinical manifestations to establish a platform for future studies on regional disparities.

Methods: Subjects were enrolled into the SCOLR study from June 2016 to June 2017 using the Systemic Lupus International Collaborating Clinic (SLICC) classification criteria for SLE. Retrospective review of medical records as well as clinical visits yielded more than 80 variables including demographic and clinical data, disease activity, comorbidities, serologic identifiers for SLE, and treatment history. Data involving clinical manifestations including renal involvement were analyzed with descriptive statistics.

Results: Of the 147 subjects enrolled, the majority resided in the surrounding geographic areas of the participating institution (Loma Linda University Medical Center). Ninety-two percent (135) were women and 8% (12) were men (female:male ratio, 11) with a mean age of 42 years (range 19-85). Thirty-seven percent were White non-Hispanic, 37% White Hispanic, 10% Asian, and 16% Black. Positive antinuclear antibody was demonstrated in 90%, dsDNA antibody in 52%, and Smith antibody in 34% of subjects. Lupus nephritis was noted in 46 subjects, of whom greater than 50% were of Hispanic origin. SLEDAI score was also notably greater in the Hispanic population compared to other subsets.

Conclusion: Subjects with SLE residing in the Inland Empire demonstrate findings in line with other cohorts with greater disease activity and severity among non-White groups compared to Whites and Hispanic subjects specifically in our cohort appearing to be at greater risk of morbidity and mortality. Our preliminary data warrants further analysis of racial/ethnic subsets in serologies and disease manifestations.

Table 1. Baseline Characteristics

Current age, average (range)

42 (19-85)

Disease duration, average (range)

10.6 (1-46)

Female, n (%)

135 (92)

Race / Ethnicity (n)

White Hispanic

55

White non-Hispanic

55

Black

23

Asian/Pacific-Islander

14

Serologies (n, %)

Antinuclear Antibody

105/117 (90%)

dsDNA Antibody

66/128 (52%)

Smith Antibody

38/113 (34%)

Anti-Ro/SSA antibody

46/85 (54%)

Anti-La/SSB antibody

15/81 (19%)

Ribonucleoprotein antibody

40/90 (44%)

Lupus anticoagulant

21/84 (25%)

Beta-2gp IgM

6/ 73 (8%)

Beta-2gp IgG

7/ 62 (11%)

Cardiolipin IgM

19/93 (20%)

Cardiolipin IgG

11/72 (15%)

Clinical manifestations (%)

Mucocutaneous abnormalities

96/124 (77%)

Serositis

36/117 (31%)

Arthritis

94/123 (76%)

Hematologic abnormalities

45/117 (38%)

Lupus nephritis

46/147 (31%)

White non-Hispanic

6

White Hispanic

26

Asian

6

Black

8

Treatment history (current or prior)

Hydroxychloroquine

97%

Azathioprine

46%

Mycophenolate

42%

Cyclophosphamide

23%

Belimumab

22%

Prednisone

75%

SLEDAI score

0

10

1-5 (mild)

38

6-10 (moderate)

22

>10 (severe

10


Disclosure: J. Liu, None; K. Teves, None; V. La, None; A. Bravo, None; S. Lezcano, None; T. Khawar, None; E. Sadeghi, None; C. B. Wang, None; K. Torralba, None; H. Yang, None; V. K. Sandhu, None.

To cite this abstract in AMA style:

Liu J, Teves K, La V, Bravo A, Lezcano S, Khawar T, Sadeghi E, Wang CB, Torralba K, Yang H, Sandhu VK. The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-southern-california-lupus-registry-i-baseline-characteristics-of-patients-with-systemic-lupus-erythematosus-in-an-uncharted-territory/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-southern-california-lupus-registry-i-baseline-characteristics-of-patients-with-systemic-lupus-erythematosus-in-an-uncharted-territory/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology